Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 265
- Registration Number
- NCT04913571
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis
Phase 3
- Conditions
- Colorectal CancerLiver Metastases
- Interventions
- Drug: Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT04912258
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC
Not yet recruiting
- Conditions
- Colorectal CancerCirculating Tumor Cell
- Interventions
- Diagnostic Test: Circulating tumor cell
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1000
- Registration Number
- NCT04912882
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Phase 3
- Conditions
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT04912271
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I
- Conditions
- Gynecologic Cancer
- Interventions
- Device: Multi-cancer early detection test
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 495
- Registration Number
- NCT04903665
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC
Not Applicable
Recruiting
- Conditions
- De-escalationImmune Checkpoint InhibitorOropharyngeal Carcinoma
- Interventions
- Other: Toxicities reduced treatment arm
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT04867330
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, China
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Recruiting
- Conditions
- RecurrenceCholangiocarcinomaGall Bladder CancerBiliary Tract Neoplasms
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04856761
- Locations
- 🇨🇳
Huashan hospital, Shanghai, China
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
Not Applicable
Recruiting
- Conditions
- Borderline Resectable Pancreatic Cancer
- Interventions
- Procedure: Laparoscopic pancreatoduodenectomyProcedure: Open pancreatoduodenectomy
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04855331
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 224
- Registration Number
- NCT04850625
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Phase 2
- Conditions
- Cancer of Unknown Primary
- Interventions
- Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT04848597
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath